Anti-CD22 antibody-drug conjugates (ADC) inotuzumab ozogamicin and moxetumomab pasudotox, were approved for B-cell acute lymphoblastic leukemia (ALL) and hairy cell leukemia, respectively (24, 25). Here, CD22 is linked to acute lymphoblastic leukemia.